On June 23, 2025, Emergent BioSolutions Inc. reported a contract option modification worth $62.4 million with the U.S. Department of Health and Human Services for supplying Botulism Antitoxin. This modification is part of a 10-year contract intended for treating symptomatic botulism in patients.